EKSO Trial: Powered Exoskeleton for Ambulation in Subjects With Spinal Cord Injury (SCI)
Key facts
- Who runs it
- Shirley Ryan AbilityLab
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 40 people, planned
- Started
- May 2012
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Treatments tested
- Ekso exoskeleton
- Record updated
- 22 October 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (19)Hide the full registry criteria
Who can take part
- Participants must:
- have a spinal cord injury SCI between C7-S1
- be between 18-65 years of age
- be able to physically fit into the exoskeletal device
- be able to tolerate upright standing for a minimum of 30 minutes
- have joint range of motion (ROM) within normal functional limits for ambulation
- have sufficient upper body strength to balance themselves using the walker while wearing the exoskeleton
- have a different neurological weakness than SCI but fit the other inclusion criteria above
Who cannot take part
- Height below 62 inches or above 74 inches
- Weight above 220 lbs
- Joint contractures of any extremity that limits normal ROM during ambulation with assistive devices
- Any medical issue that precludes full weight bearing and ambulation (e.g. orthopedic injuries, pain, severe spasticity)
- Skin issues that would prevent wearing the device
- Cognitive and/or communicative disability (e.g. due to brain injury). Patients must be able to follow directions well and demonstrate learning capability
- Significant Osteoporosis: Osteoporosis will be graded based on the T score that indicates a person's bone mineral content and is graded as follows: (14); T +1: Normal bone density:
- T -1 to -2.5: Low bone density of osteopenia
- T -2.5 to -3.0: osteoporosis
- T <-3.0: Severe osteoporosis
- If the patient has severe osteoporosis and a T score of <-3, participation in the study will be considered based upon their physicians recommendation and overall evaluation of the patient
Where in United States
- Rehabilitation Institute of ChicagoChicago, United States
About the trial
What the trial wants to find out
This study seeks to test the safety and efficacy of the Esko device in SCI population and in populations with similar neurological weakness to the SCI population. The device can currently stand from a seated position, walk, and turn and sit down. Our hypothesis are as follows:
Read full original descriptionShow less
* Hypothesis 1: We hypothesize that the Ekso subject will significantly improve balance while wearing the device as noted by subject's ability to safely achieve standing balance for 30 sec without loss of balance. * Hypothesis 2: We hypothesize that the Ekso subject will display improved ability to safely ambulate 10 meters to be assessed using the 10 meter walk test. * Hypothesis 3: We hypothesize that the Ekso subject will display improved weight shift in both static and dynamic activities as determined by a trained physical therapist. * Hypothesis 4: We hypothesize that the Ekso subject will verbalize improved success with training of the device as noted by subjective questionnaires that will be assessed following each training session.
The group in the trial
- Ekso Safety and EfficacyTreatment being tested
Observational study on the first time use of a robotic exoskeleton.
Treatment: Ekso exoskeleton
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Investigational Study of the Ekso Powered Exoskeleton for Ambulation in Individuals With Spinal Cord Injury (or Similar Neurological Weakness)
- Record updated
- 22 October 2026